Vital Farms, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VITL research report →
Range $9 – $18
Price Chart
About the company
Vital Farms, Inc. is a values-driven food enterprise dedicated to providing ethically sourced, pasture-raised products across the United States. Its diverse product portfolio primarily features a variety of egg-based items, such as fresh shell eggs, convenient hard-boiled eggs, liquid whole eggs, and popular egg bites, alongside dairy selections like butter and ghee.
- CEO
- Russell Diez-Canseco
- IPO
- 2020
- Employees
- 739
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on VITL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $373.11M
- P/E
- -17.97
- Fwd P/E
- 316.00
- PEG
- 0.28
- P/S
- 0.55
- P/B
- 1.47
- EV/EBITDA
- 332.61
- Div Yield
- 0.00%
- Gross Margin
- 24.37%
- Op Margin
- -3.84%
- Net Margin
- -3.03%
- ROE
- -7.29%
- ROIC
- -4.72%
Latest fiscal year · YoY change
- Revenue
- $759.44M+25.3%
- Gross Profit
- $285.68M+24.2%
- Op Income
- $88.37M
- Net Income
- $66.28M+24.2%
- EPS
- $1.49+19.2%
- OCF Growth
- -47.7%
- FCF Growth
- -234.9%
- 52W High
- $36.10
- 52W Low
- $7.95
- 50D MA
- $9.52
- 200D MA
- $12.70
- Beta
- 1.15
- RSI (14)
- 44
- Avg Volume
- 1.77M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vital Farms posted sequential Q3 improvement, but weaker-than-expected demand and slower new distribution forced management to cut full-year sales and EBITDA guidance and withdraw its 2030 targets.· November 3, 2026
- Q3 net revenue was $182.2 million, down $16.8 million or 8.4% year over year, but up 10% sequentially from Q2.
- Adjusted EBITDA improved to $1.5 million from a $26.6 million loss in Q2, while gross margin rose to 23.1% from much lower levels in Q2.
- Management now expects full-year 2026 net sales of about $730 million and adjusted EBITDA of about negative $15 million, versus prior guidance of $775 million to $800 million and $0 to $10 million.
- Distribution gains were strong, with average selling TDPs above 175 in Circana MULO+ and record third-quarter share of 7.2% dollar share and 2.3% volume share of shell eggs.
- The company withdrew its 2030 financial targets, saying it needs more progress on margins and profitability before revisiting long-term goals.
Q3 2026 net revenue was $182.2 million, down $16.8 million or 8.4% year over year; gross profit was $42.1 million and gross margin was 23.1%; adjusted EBITDA was $1.5 million versus a loss of $26.6 million in Q2. Thilo Wrede said the year-over-year revenue decline was mainly driven by $14.3 million from lower price/mix and $2.2 million from lower volume (excluding breaker and wholesale), with breaker and wholesale contributing about $0.3 million to the decline. SG&A was $38.1 million, down $6.3 million or 14% year over year, shipping and distribution was $11.7 million versus $9.2 million a year ago, cash was $84 million, debt was $117.6 million, capex was $14.3 million in Q3 and $51.7 million year-to-date, and full-year capex is still expected to be $70 million to $75 million. Updated full-year guidance is about $730 million in net sales and about negative $15 million in adjusted EBITDA, versus prior guidance of $775 million to $800 million and $0 to $10 million; management also expects modest sequential gross margin improvement in Q4, but not the previously expected move into the 30s.
Russell Diez-Canseco said the main issue this year was not branded competition so much as the normalization of egg supply after years of bird flu-driven scarcity, which pulled light buyers back to private label. He said Vital Farms is shifting back to a more normal pricing and promotional approach, focusing on being competitive at retail while being more selective on where it invests. His tone was candid and more cautious than in prior quarters: he emphasized that the company still sees a large long-term opportunity, but it is withdrawing its 2030 targets and focusing on near-term execution, margin recovery, and profitability.
Thilo Wrede focused on the mechanics of the guidance reset and the path to better margins. He said the revenue outlook was reduced by three main factors: weaker seasonal demand than expected, a more conservative assumption on holiday pricing, and later-than-planned new distribution placements. He also pointed to lower breaker volumes and supply-management costs as key to the sequential gross margin recovery, said breaker was about an $8 million EBITDA impact in Q3 versus $21 million in Q2, and reiterated that SG&A efficiency actions should reduce the annualized run rate by about $6 million to $7 million. On capital allocation, he said most of the Vital Crossroads enclosure spending will occur this year, capex is still guided to $70 million to $75 million, and the cash balance is being kept as an “insurance policy” to preserve flexibility.
Analysts pressed management on why pricing strategy changed, whether the quarter’s guidance cut was mostly a gross margin issue or mainly a sales issue, and how to think about the delayed distribution wins. Russell said the company now believes its price premium versus private label is back to roughly the mid-2023 level and that many lost households likely returned to private label rather than to other branded eggs. On guidance, Thilo said the revision is primarily driven by lower revenue assumptions and only secondarily by gross margin, while Russell said the delayed distribution was a common operational challenge and not indicative of a structural issue. Questions also focused on 2027 setup, with Thilo saying future upside could come from continued reduction in breaker volumes, better leverage from distribution ramp, feed-cost savings, and the end of butter sales, which are margin dilutive.
Management still sees the brand as growing from a much larger base than in 2023, with Q3 net revenue up about 65% versus $110 million in Q3 2023 and share gains continuing. Distribution is expanding, TDPs are above 175, and the company says the new shelf space is now in place and should continue to ramp over time. The company also believes supply is now better aligned with demand, which should support margins as breaker volumes fall and operational efficiency improves.
The core risk is that the company’s recent growth was partly boosted by temporary bird flu-driven pricing distortions, and management now believes much of that demand proved transitory. Q4 demand signals are softer than expected, seasonal pricing lift is no longer assumed, and some new distribution arrived late, all of which pressured guidance. Management also withdrew its 2030 targets, signaling that margin expansion and profitability are taking longer than hoped.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.9%
- Shares Outstanding
- 42.94M
- Float Shares
- 35.17M
of shares held by institutions
249 13F filers
Buy/sell ratio 1.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.79M | ▲ 617.17K |
| Vanguard Group Inc | 2.85M | ▲ 530.01K |
| Divisadero Street Capital Management, LP | 1.87M | ▼ 129.84K |
| Jpmorgan Chase & Co | 1.57M | ▲ 568.09K |
| Vanguard Capital Management LLC | 1.50M | ▼ 25.65K |
| Goldman Sachs Group Inc | 1.46M | ▼ 4.81K |
| Two Sigma Investments, LP | 1.33M | ▲ 622.58K |
| Citadel Advisors LLC | 1.30M | ▲ 640.44K |
| Bnp Paribas Financial Markets | 1.26M | ▲ 522.60K |
| Cibc World Market Inc. | 1.13M | ▲ 10.69K |
| Needham Investment Management LLC | 1.01M | ▼ 198.25K |
| Geode Capital Management, LLC | 880.20K | ▼ 75.84K |
Held by 233 ETFs
Biggest fund positions in VITL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | OHAYER MATTHEW | sell | 23,250 |
| Nov 16, 26 | Coon Stephanie | other | 500 |
| Nov 16, 26 | Pappas Peter Nicholas | other | 500 |
| Nov 16, 26 | Diez-Canseco Russell | other | 500 |
| Nov 16, 26 | Wrede Thilo | other | 500 |
| Nov 11, 26 | OHAYER MATTHEW | sell | 23,250 |
| Nov 6, 26 | OHAYER MATTHEW | sell | 3,550 |
| Nov 9, 26 | OHAYER MATTHEW | sell | 66,200 |
| Sep 16, 26 | Van Hoven Reena Chauhan | other | 344 |
| Sep 2, 26 | Holland Joseph Michael | other | 412 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VITL coverage
Recent articles, reports, and earnings notes.
No research on VITL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VITL report →Vital Infrastructure Property Trust (VITL.UN:CA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Head to Head Survey: Vital Farms (NASDAQ:VITL) vs. Hormel Foods (NYSE:HRL)
defenseworld.net · Nov 6
Vital Farms, Inc. (VITL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Vital Farms Q3 Earnings Call Highlights
marketbeat.com · Nov 3
Vital Farms (VITL) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 3
Vital Farms Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 3
Earnings Preview: Vital Farms (VITL) Q3 Earnings Expected to Decline
zacks.com · Oct 27
Vital Farms (VITL) Stock Declines While Market Improves: Some Information for Investors
zacks.com · Oct 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.